Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Pollyea

Showing results (81-90 of 179) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2022
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and AzacitidineDaniel A Pollyea, Keith W Pratz, Andrew H Wei, et al.
Molecular Cancer Therapeutics|March 18, 2004
TNP-470 promotes initial vascular sprouting in xenograft tumorsJianzhong Huang, Jason S Frischer, Tamara New, et al.
Blood Advances|December 21, 2021
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndromeAaron T Gerds, Bart L Scott, Peter Greenberg, et al.
Blood|November 1, 2024
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AMLCurtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, et al.
Blood|September 15, 2021
The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylationMaria L Amaya, Anagha Inguva, Shanshan Pei, et al.
Haematologica|June 19, 2025
The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cellsKellen B Gil, Jamie Borg, Rosana Moreira Pereira, et al.
Journal of Leukocyte Biology|November 6, 2020
MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cellsDaniel A Pollyea, Hyun Min Kim, Brett M Stevens, et al.
Blood|August 26, 2025
Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemiaCristiana O'Brien, Nirvana Nursimulu, Anit Tyagi, et al.
Leukemia & Lymphoma|September 22, 2015
Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution seriesBrett Stevens, Julia Maxson, Jeffrey Tyner, et al.
Haematologica|December 18, 2023
Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidineAmanda C Winters, Mohd Minhajuddin, Brett M Stevens, et al.
Pageof 18

Showing results (81-90 of 179) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2022
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and AzacitidineDaniel A Pollyea, Keith W Pratz, Andrew H Wei, et al.
Molecular Cancer Therapeutics|March 18, 2004
TNP-470 promotes initial vascular sprouting in xenograft tumorsJianzhong Huang, Jason S Frischer, Tamara New, et al.
Blood Advances|December 21, 2021
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndromeAaron T Gerds, Bart L Scott, Peter Greenberg, et al.
Blood|November 1, 2024
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AMLCurtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, et al.
Blood|September 15, 2021
The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylationMaria L Amaya, Anagha Inguva, Shanshan Pei, et al.
Haematologica|June 19, 2025
The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cellsKellen B Gil, Jamie Borg, Rosana Moreira Pereira, et al.
Journal of Leukocyte Biology|November 6, 2020
MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cellsDaniel A Pollyea, Hyun Min Kim, Brett M Stevens, et al.
Blood|August 26, 2025
Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemiaCristiana O'Brien, Nirvana Nursimulu, Anit Tyagi, et al.
Leukemia & Lymphoma|September 22, 2015
Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution seriesBrett Stevens, Julia Maxson, Jeffrey Tyner, et al.
Haematologica|December 18, 2023
Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidineAmanda C Winters, Mohd Minhajuddin, Brett M Stevens, et al.
Pageof 18